We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Verona Pharma Plc | LSE:VRP | London | Ordinary Share | GB00BYW2KH80 | ORD 5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 55.00 | 45.00 | 65.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMVRP
RNS Number : 9721Z
Verona Pharma PLC
20 March 2017
Verona Pharma plc
("Verona Pharma" or the "Company")
2016 Annual Report and Accounts
and
Notice of AGM
20 March 2017, London - Verona Pharma plc (AIM: VRP.L), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs, is pleased to confirm that a hard copy of the Annual Report and Accounts for the year ended 31 December 2016 ("2016 Annual Report and Accounts"), the Notice of Annual General Meeting and a Form of Proxy have been posted to Shareholders.
The Company confirms that its 2016 Annual Report and Accounts are available online at: http://www.veronapharma.com/investors/#investors-financial-performance. The Notice of Annual General Meeting can be found within the AIM Rule 26 section of the website.
The Annual General Meeting of Verona Pharma will be held at the offices of Shakespeare Martineau LLP, 6th Floor, 60 Gracechurch Street, London EC3V 0HR on 12th April 2017 at 12.00 noon.
-Ends-
For further information please contact:
Verona Pharma plc Tel: +44 (0)20 3283 4200 Jan-Anders Karlsson, Chief Executive Officer N+1 Singer Tel: +44 (0)20 7496 3000 Aubrey Powell / James White/ Alex Laughton-Scott FTI Consulting Tel: +44 (0)20 3727 1000 Simon Conway / Stephanie Cuthbert / Natalie Garland-Collins
Notes to Editors
About Verona Pharma plc
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs.
Verona Pharma's product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti--inflammatory agent in a single compound. In clinical trials, treatment with RPL554 has been observed to result in statistically significant improvements in lung function as compared to placebo and has shown clinically meaningful and statistically significant improvements in lung function when added to two commonly used bronchodilators as compared to either bronchodilator administered as a single agent. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis, and potentially asthma.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCKMGZFFGMGNZM
(END) Dow Jones Newswires
March 20, 2017 09:55 ET (13:55 GMT)
1 Year Verona Pharma Chart |
1 Month Verona Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
